Cargando…

Preparation and SPECT/CT Imaging of (177)Lu-Labeled Peptide Nucleic Acid (PNA) Targeting CITED1: Therapeutic Evaluation in Tumor-Bearing Nude Mice

PURPOSE: The expression of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 (CITED1) is upregulated in papillary thyroid carcinoma (PTC) and mediates cell proliferation and migration. To facilitate early diagnosis and monitoring of recurrent or metastatic PTC, we desig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jia, Zhang, Lei, Li, Wenbo, Lei, Chengming, Cao, Yiyi, Wang, Ying, Wang, Zhengjie, Pang, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970276/ https://www.ncbi.nlm.nih.gov/pubmed/32021292 http://dx.doi.org/10.2147/OTT.S238098

Ejemplares similares

Comparative Evaluation of Novel (177)Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting
por: Tano, Hanna, et al.
Publicado: (2021)

The role of (18)F-FCH PET/CT in patients with uremic hyperparathyroidism compared with (99m)Tc-sestaMIBI SPECT/CT and ultrasonography
por: Xue, Yu, et al.
Publicado: (2019)

Quantitative accuracy of (177)Lu SPECT imaging for molecular radiotherapy
por: Mezzenga, Emilio, et al.
Publicado: (2017)

Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
por: Beauregard, Jean-Mathieu, et al.
Publicado: (2011)

Accuracy of (177)Lu activity quantification in SPECT imaging: a phantom study
por: Uribe, Carlos F., et al.
Publicado: (2017)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Comprehensive SPECT/CT system characterization and calibration for (177)Lu quantitative SPECT (QSPECT) with dead-time correction
por: Frezza, Andrea, et al.
Publicado: (2020)

Simultaneous Visualization of (161)Tb- and (177)Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
por: Borgna, Francesca, et al.
Publicado: (2021)

Priming increases the anti-tumor effect and therapeutic window of (177)Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1
por: Dalmo, Johanna, et al.
Publicado: (2017)

Improving quantitative dosimetry in (177)Lu-DOTATATE SPECT by energy window-based scatter corrections
por: de Nijs, Robin, et al.
Publicado: (2014)

In vivo quantification of (177)Lu with planar whole-body and SPECT/CT gamma camera imaging
por: Bailey, Dale L., et al.
Publicado: (2015)

Impact of dead time on quantitative (177)Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
por: Desy, Alessandro, et al.
Publicado: (2020)

Reconstructed SPECT images of (177)Lu homogeneous cylindrical phantom used for calibration and texture analysis
por: Mezzenga, Emilio, et al.
Publicado: (2022)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

Quantitative accuracy of (177)Lu SPECT reconstruction using different compensation methods: phantom and patient studies
por: Hippeläinen, Eero, et al.
Publicado: (2016)

SPECT image segmentation for estimation of tumour volume and activity concentration in (177)Lu-DOTATATE radionuclide therapy
por: Gustafsson, Johan, et al.
Publicado: (2017)

Towards accurate (177)Lu SPECT activity quantification and standardization using lesion-to-background voxel ratio
por: Raskin, Stanislav, et al.
Publicado: (2023)

Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points
por: Chen, Gefei, et al.
Publicado: (2023)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Fast GPU-based Monte Carlo code for SPECT/CT reconstructions generates improved (177)Lu images
por: Rydén, T., et al.
Publicado: (2018)

Texture analysis in (177)Lu SPECT phantom images: Statistical assessment of uniformity requirements using texture features
por: Sarnelli, Anna, et al.
Publicado: (2019)

Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
por: Desy, Alessandro, et al.
Publicado: (2022)

CD38‐Targeted Theranostics of Lymphoma with (89)Zr/(177)Lu‐Labeled Daratumumab
por: Kang, Lei, et al.
Publicado: (2021)

Transcriptional effects of (177)Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice
por: Spetz, Johan, et al.
Publicado: (2019)

Polymer composite microspheres loading (177)Lu radionuclide for interventional radioembolization therapy and real-time SPECT imaging of hepatic cancer
por: Xiao, Liu, et al.
Publicado: (2023)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
por: Delker, Astrid, et al.
Publicado: (2023)

The effect of calibration factors and recovery coefficients on (177)Lu SPECT activity quantification accuracy: a Monte Carlo study
por: Ramonaheng, Keamogetswe, et al.
Publicado: (2021)

Quantitative (177)Lu SPECT/CT imaging for personalized dosimetry using a ring-shaped CZT-based camera
por: Danieli, Rachele, et al.
Publicado: (2023)

(177)Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice
por: Repetto-Llamazares, Ada H. V., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_eqo0k1juoaoentmcee0rlbkf9r